Clinical trials: Minimal Disease, Residual
Multiple Myeloma
Risk-adapted Therapeutic Strategy in +1q NDMM
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal…
- Trial name
- NCT07045168
- Testing
- risk-scoring model
- Where
- China
- Volunteers
- 200 people
- Sponsor
- FengYan Jin
Gastric Cancer, ctDNA
Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description
This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy
- Trial name
- NCT05029869
- Testing
- ctDNA
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Colorectal Cancer
Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease
The goal of this clinical research study is to learn about the effects of biomarkertargeted therapy on ctDNA in patrticipants with CRC and MRD. This is an observational study.
- Trial name
- NCT06878131
- Testing
- Colorectal Cancer
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Minimal Residual Disease, Fertility Preservation
Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors
For prepubertal patients, cryopreservation of testicular tissue is the only option available to preserve their fertility before cancer treatment.
- Trial name
- TESTIMAR (NCT02400970)
- Testing
- malignant cells
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Myeloid Leukemia
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.
- Trial name
- NCT04209712
- Testing
- haploid allogeneic NK cell therapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
MCLA-117 in Acute Myelogenous Leukemia
This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.
- Trial name
- NCT03038230
- Testing
- MCLA-117 bispecific antibody
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 80 people
- Sponsor
- Merus B.V.
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission…
- Trial name
- NCT03070093
- Testing
- gilteritinib
- Where
- 39 sites in United States, Canada and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement.
- Trial name
- NCT07854652
- Testing
- Ifupinostat Hydrochloride
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose.
- Trial name
- NCT05536700
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia.
- Trial name
- NCT00005619
- Testing
- polymerase chain reaction, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Northwestern University
Neoplastic Pathology, Autopreserved Ovarian Tissue
Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic Pathology
Cryopreservation of ovarian tissue is offered to young girls and women aged under 35 who have to undergo sterilizing gonadotoxic treatment, with the aim of preserving their fertility.
- Trial name
- OVAGRAFT (NCT02888145)
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Leukemia
Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial
RATIONALE: Testing for minimal residual disease in blood samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment.
- Trial name
- NCT01629745
- Testing
- gene expression analysis, flow cytometry, laboratory biomarker analysis
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia
Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.
- Trial name
- FERTILAM (NCT04679285)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
- Trial name
- NCT07191717
- Testing
- Abemaciclib, Biospecimen Collection, Imlunestrant
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
We propose to conduct an ancillary prospective evaluation of the impact of Dara-Len-Dex discontinuation after 2 years, on the persistence of MRD negativity in patients that were MRD negative at 2 years.
- Trial name
- MRD-CONFIRM (NCT05203003)
- Testing
- Assessment of MRD
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Triple Negative Breast Cancer
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) surveillance component and a therapeutic component.
- Trial name
- c-TRAK-TN (NCT03145961)
- Testing
- Pembrolizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 208 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Cervical Cancer
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer.
- Trial name
- NCT05872724
- Testing
- Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab, Chemoradiotherapy (small pelvic) + Zimberelimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Suzhou Municipal Hospital
Multiple Myeloma
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
To assess whether continued treatment to achieve negative Minimal Residual Disease and Imaging (MRDI(-)) improves therapeutic outcomes in patients with newly diagnosed Multiple Myeloma.
- Trial name
- NCT05697913
- Testing
- Continued treatment adapted to the response
- Volunteers
- 66 people
- Sponsor
- Hospital Galdakao-Usansolo
Follicular Lymphoma
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.
- Trial name
- FIL_GAZEBO (NCT05929222)
- Testing
- Radiotherapy, Radiotherapy plus Obinutuzumab
- Where
- 49 sites in Italy
- Volunteers
- 190 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Gastric / Gastroesophageal Junction Adenocarcinoma
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
For locally advanced gastric adenocarcinoma/esophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including…
- Trial name
- MRD-ATLAS-III (NCT07508956)
- Testing
- Standard neoadjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy, Radical gastrectomy, Standard adjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Shanghai Zhongshan Hospital